Failure to adhere to medicinal treatment regimens is arguably the world’s biggest therapeutic challenge.The R&D spend on the discovery and extension of the drug pipeline in 2018 was reported at $179 billion, some 21.6% of sales (1). Given that typical adherence levels on average sit around 50% non-adherenceto long-term therapy for chronic illnesses, intentional and unintentional medication non-adherence signifies a prevalent and persistent healthcare problem…
This article is taken from Pharmaceutical Manufacturing and Packing Sourcer February 2020, pages 22-28. © Samedan Ltd
